BMRN vs PRLD · P/E 40, rev $2.85B vs rev $6.5M
Biomarin Pharmaceutical Inc (BMRN) versus Prelude Therapeutics Inc (PRLD) — a side-by-side from cached financials, not a winner call.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
Prelude Therapeutics Inc (PRLD) is a biotechnology company listed on NASDAQ.
Latest reported BMRN revenue for 2024-12-31 was $2.85B. Net income was $426.9M. Revenue was up 18.0% from 2023-12-31 to 2024-12-31. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Latest reported PRLD revenue for 2025-09-30 was $6.5M. Net income was -$83.0M. Revenue was up 116.7% from 2024-09-30 to 2025-09-30. PRLD currently screens at market cap $346.5M.
BMRN currently screens at market cap $10.63B and trailing P/E 39.6. PRLD currently screens at market cap $346.5M.
Not investment advice. Open the BMRN and PRLD stock pages for the full models.
Not investment advice.